Announcements Trials
Browse Landscape

Phase

Phase 2 57Phase 3 47Phase 1 24Phase 1/2 11Phase 2/3 8Phase NA 7Phase EARLY_PHASE1 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Central Nervous System Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 12pembrolizumab 8Nivolumab 8Biopsy 7Radiotherapy 6Temozolomide 4Specimen Handling 4Radiosurgery 4Cyclophosphamide 4fludarabine 3X-Rays 3Surgical Procedures, Operative 3Paclitaxel 3Leukapheresis 3Ipilimumab 3Fluorodeoxyglucose F18 3Aspirin 3perflutren 2alovudine 2Tirzepatide 2Rituximab 2Positron-Emission Tomography 2Phantoms, Imaging 2Omeprazole 2Niacinamide 2Neoadjuvant Therapy 2Losartan 2Letrozole 2Ketoconazole 2Immunotherapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Radiation × 90 days × Clear all
NCT03554707 2026-05-08

SGT-53 in Children With Recurrent or Progressive CNS Malignancies

SynerGene Therapeutics, Inc.

Phase EARLY_PHASE1 Withdrawn
CNS

Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡